Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Rating) SVP Samantha Pearce sold 531 shares of the stock in a transaction on Tuesday, January 3rd. The shares were sold at an average price of $159.59, for a total value of $84,742.29. Following the sale, the senior vice president now owns 11,309 shares of the company’s stock, valued at approximately $1,804,803.31. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.
Samantha Pearce also recently made the following trade(s):
- On Tuesday, December 13th, Samantha Pearce sold 531 shares of Jazz Pharmaceuticals stock. The shares were sold at an average price of $155.45, for a total value of $82,543.95.
- On Thursday, November 10th, Samantha Pearce sold 1,063 shares of Jazz Pharmaceuticals stock. The shares were sold at an average price of $155.00, for a total value of $164,765.00.
Jazz Pharmaceuticals Price Performance
Shares of NASDAQ:JAZZ traded down $1.09 during trading on Thursday, reaching $159.38. 595,795 shares of the company’s stock traded hands, compared to its average volume of 603,565. Jazz Pharmaceuticals plc has a fifty-two week low of $125.36 and a fifty-two week high of $169.98. The company has a quick ratio of 2.27, a current ratio of 3.16 and a debt-to-equity ratio of 2.07. The firm has a market cap of $10.04 billion, a PE ratio of -531.27, a P/E/G ratio of 0.85 and a beta of 0.74. The company has a 50-day simple moving average of $152.11 and a 200-day simple moving average of $149.94.
Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Rating) last posted its earnings results on Wednesday, November 9th. The specialty pharmaceutical company reported $4.53 EPS for the quarter, beating analysts’ consensus estimates of $4.35 by $0.18. Jazz Pharmaceuticals had a positive return on equity of 30.71% and a negative net margin of 0.52%. The firm had revenue of $940.65 million for the quarter, compared to analysts’ expectations of $939.88 million. As a group, analysts predict that Jazz Pharmaceuticals plc will post 14.77 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several research firms recently issued reports on JAZZ. The Goldman Sachs Group raised Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and cut their target price for the company from $192.00 to $190.00 in a research report on Thursday, December 8th. StockNews.com raised Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Monday, November 21st. Needham & Company LLC cut their price target on Jazz Pharmaceuticals from $210.00 to $208.00 and set a “buy” rating on the stock in a research report on Thursday, November 10th. Finally, Royal Bank of Canada increased their price target on Jazz Pharmaceuticals from $206.00 to $207.00 and gave the stock an “outperform” rating in a research report on Thursday, November 10th. One investment analyst has rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Jazz Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $202.33.
Institutional Investors Weigh In On Jazz Pharmaceuticals
Institutional investors have recently modified their holdings of the business. Fifth Third Bancorp lifted its stake in Jazz Pharmaceuticals by 32.9% in the 2nd quarter. Fifth Third Bancorp now owns 279 shares of the specialty pharmaceutical company’s stock valued at $44,000 after buying an additional 69 shares in the last quarter. Captrust Financial Advisors lifted its stake in Jazz Pharmaceuticals by 2.4% in the 1st quarter. Captrust Financial Advisors now owns 3,707 shares of the specialty pharmaceutical company’s stock valued at $577,000 after buying an additional 86 shares in the last quarter. Securian Asset Management Inc. lifted its stake in Jazz Pharmaceuticals by 1.8% in the 3rd quarter. Securian Asset Management Inc. now owns 5,781 shares of the specialty pharmaceutical company’s stock valued at $771,000 after buying an additional 100 shares in the last quarter. Quadrant Capital Group LLC lifted its stake in Jazz Pharmaceuticals by 90.3% in the 3rd quarter. Quadrant Capital Group LLC now owns 215 shares of the specialty pharmaceutical company’s stock valued at $29,000 after buying an additional 102 shares in the last quarter. Finally, Great Lakes Advisors LLC lifted its stake in Jazz Pharmaceuticals by 7.5% in the 3rd quarter. Great Lakes Advisors LLC now owns 1,586 shares of the specialty pharmaceutical company’s stock valued at $211,000 after buying an additional 110 shares in the last quarter. 89.79% of the stock is currently owned by institutional investors and hedge funds.
Jazz Pharmaceuticals Company Profile
(Get Rating)
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Jazz Pharmaceuticals, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Jazz Pharmaceuticals wasn’t on the list.
While Jazz Pharmaceuticals currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Be the first to comment